Senseonics announces an agreement to take over the commercialization and distribution of Eversense 365 from Ascensia Diabetes Care.
Brian Hansen to become Senseonics' Chief Commercial Officer.
Non-dilutive debt facility expanded to $100 million with Hercules Capital for commercial organization funding.
Transition of Commercial Operations
Senseonics will assume global sales and marketing responsibility for Eversense 365 from January 1, 2026.
Appointment of Chief Commercial Officer
Brian Hansen, former President of CGM at Ascensia, to join Senseonics as Chief Commercial Officer on January 1, 2026.
Financial Impact
Expectations of revenue improvement and gross margin expansion to 50% in 2026, aiming for over 70% at scale.
- The transition aims to enhance market responsiveness and accelerate Eversense growth.
- Direct control over commercialization is expected to improve customer experience and increase revenue.
Senseonics' strategic move to internalize Eversense commercial operations shows commitment to growth and improving market position.